FDA Panel Delays Review of Gen-Probe's Progensa PCA3 Assay | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – A US Food and Drug Administration panel will not review Gen-Probe's submission for clearance of its Progensa PCA3 assay for prostate cancer in October as previously scheduled, the San Diego-based company disclosed in a regulatory filing after the close of the market Monday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.